- Details
- Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer. Dr. Powles discusses the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. He emphasizes the study's practice-changing potential, noting the b...
|
- Details
- Christos Kyriakopoulos discusses the phase 1/2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer. Dr. Kyriakopoulos discusses the trial design, focusing on the completed phase 1 results and ongoing phase 2 study. The phase 1 data show the combination is well-tolerated with promising efficacy, including an 88% PSA-90 response rate in evaluable patients. The t...
|
- Details
- Zachary Klaassen interviews Hiroshi Kitamura about the JCOG1019 study, examining watchful waiting versus BCG therapy in high-grade T1 bladder cancer patients with no residual tumor after second TUR. Dr. Kitamura explains the trial design and key results, highlighting that watchful waiting demonstrates non-inferiority to BCG in relapse-free survival for T1 or deeper recurrence. The study shows simi...
|
- Details
- Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials. Biographies: Oliver Sartor, MD , Medical Oncologist, Professor of Medicine, Urology and Radiology, Director, Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Zachary Klaassen, MD, MSc , Urologic Oncologist, Assistan...
|
- Details
- Leslie Ballas interviews Chad Tang about the use of stereotactic body radiation therapy (SBRT) in metastatic renal cell carcinoma (RCC). Dr. Tang discusses two key approaches: treating oligometastatic disease (up to five metastatic sites) and oligoprogressive disease (one to three progressing sites). He presents data from recent studies showing SBRT's potential to delay the need for systemic thera...
|
- Details
- Fred Saad and Neal Shore discuss the ARANOTE trial with Zach Klaassen, exploring the use of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's diverse patient population and impressive results, including a 46% reduction in radiographic progression-free survival risk. The conversation covers the efficacy of this doublet therapy in various subgroups, pa...
|
- Details
- Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Mehra discusses the trial's design, which focuses on four subgroups: mismatch repair deficiency, high tumor mutational burden, CDK12 inactivation, and BRCA2 m...
|
- Details
- Leslie Ballas interviews Syed Hussain about histologic subtypes of bladder cancer. Dr. Hussain discusses the challenges in diagnosing and managing variant histologies, emphasizing their poor prognosis and the need for specialized research. He highlights the importance of central pathology review and the potential differences in treatment response among subtypes. Dr. Hussain advocates for focused i...
|
- Details
- Laura Bukavina joins Ashish Kamat to discuss the cancer microbiome and nutrition session at the BCAN Think Tank. Dr. Bukavina discusses key presentations on fecal microbiota transplants (FMT) in cancer treatment, highlighting promising results in lung cancer and melanoma. She emphasizes the potential of FMT to improve treatment responses and reduce toxicity. The conversation covers NCI funding opp...
|
- Details
- Sam Chang interviews Ignacio Duran about the highlights of ESMO 2024 in non-prostate genitourinary oncology. Dr. Duran discusses key findings in kidney and bladder cancer. For kidney cancer, he highlights studies challenging the sequencing of checkpoint inhibitors and new treatment options for non-clear cell carcinoma. In bladder cancer, Dr. Duran reviews three studies that could impact clinical p...
|
